Datapoint: Sanofi and Regeneron Snag Pediatric Dupixent Nod

The FDA last week approved Sanofi and Regeneron’s Dupixent for the treatment of atopic dermatitis in young children, aged between six months and five years, who have not responded to previously prescribed topical therapies. It will be the first biologic medicine available to this age group for this indication. In the atopic dermatitis market basket, Dupixent already holds covered or better status for 89% of all insured lives under the pharmacy benefit. About 38% of insured lives have preferred access to Dupixent with utilization management restrictions applied.

SOURCE: MMIT Analytics, as of 6/8/22

0 Comments
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
June 23

Datapoint: Skyrizi Scores Crohn’s Disease Nod

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
June 22

Datapoint: Merck-Seagen Deal Could Be in the Works

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
June 21

Datapoint: Centene Settles New Mexico Medicaid Dispute

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today